OTCPK:BOPC.F

Stock Analysis Report

Executive Summary

BioPharma Credit PLC, an investment trust company, invests in interest-bearing debt assets secured by royalties or other cash flows derived from royalties or sales of approved life sciences products.

Snowflake

Fundamentals

Fair value with moderate growth potential.

Share Price & News

How has BioPharma Credit's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

BOPC.F

2.6%

US Capital Markets

1.3%

US Market


1 Year Return

n/a

BOPC.F

1.2%

US Capital Markets

5.9%

US Market

Return vs Industry: Insufficient data to determine how BOPC.F performed against the US Capital Markets industry.

Return vs Market: Insufficient data to determine how BOPC.F performed against the US Market.


Shareholder returns

BOPC.FIndustryMarket
7 Day0%2.6%1.3%
30 Day1.0%-4.7%-1.9%
90 Dayn/a-3.3%-1.8%
1 Yearn/a3.4%1.2%8.3%5.9%
3 Yearn/a51.2%42.7%45.6%36.2%
5 Yearn/a78.0%61.6%66.1%47.9%

Price Volatility Vs. Market

How volatile is BioPharma Credit's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioPharma Credit undervalued compared to its fair value and its price relative to the market?

10.66x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: BOPC.F ($1.01) is trading above our estimate of fair value ($0.6)

Significantly Undervalued: BOPC.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BOPC.F is good value based on its PE Ratio (10.7x) compared to the Capital Markets industry average (37.3x).

PE vs Market: BOPC.F is good value based on its PE Ratio (10.7x) compared to the US market (17.5x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate BOPC.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BOPC.F is good value based on its PB Ratio (1x) compared to the US Capital Markets industry average (6.5x).


Next Steps

Future Growth

How is BioPharma Credit forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BOPC.F's forecast earnings growth (23% per year) is above the savings rate (2.7%).

Earnings vs Market: BOPC.F's earnings (23% per year) are forecast to grow faster than the US market (14.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if BOPC.F's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if BOPC.F's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if BOPC.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BioPharma Credit performed over the past 5 years?

137.0%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if BOPC.F's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare BOPC.F's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.

Earnings vs Industry: BOPC.F earnings growth over the past year (137%) exceeded the Capital Markets industry 36.2%.


Return on Equity

High ROE: BOPC.F's Return on Equity (8.2%) is considered low.


Return on Assets

ROA vs Industry: BOPC.F has a higher Return on Assets than the Capital Markets industry average last year.


Return on Capital Employed

ROCE Improving: Insufficient data to calculate BOPC.F's Return on Capital Employed to determine if it has improved over the past 3 years.


Next Steps

Financial Health

How is BioPharma Credit's financial position? (This company is analysed differently as a bank or financial institution)


Financial Position Analysis


Debt to Equity History and Analysis


Balance Sheet

Inventory Level: BOPC.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BOPC.F's debt is covered by short term assets.


Financial Institutions Analysis

Asset Level: BOPC.F's level of assets compared to its equity is low.

Allowance for Bad Loans: Insufficient data to determine if BOPC.F has a sufficient allowance for bad loans.

Low Risk Liabilities: BOPC.F reports no customer deposits, loans are made up entirely of externally borrowed funds.

Loan Level: Insufficient data to determine if BOPC.F has an acceptable proportion of non-loan assets held.

Low Risk Deposits: BOPC.F has advanced significantly more loans than the customer deposits it holds.

Level of Bad Loans: Insufficient data to determine if BOPC.F has an appropriate level of bad loans.


Next Steps

Dividend

What is BioPharma Credit's current dividend yield, its reliability and sustainability?

7.14%

Current Dividend Yield


Dividend Yield vs Market

company7.1%marketbottom25%1.5%markettop25%3.8%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: BOPC.F's dividend (7.14%) is higher than the bottom 25% of dividend payers in the US market (1.47%).

High Dividend: BOPC.F's dividend (7.14%) is in the top 25% of dividend payers in the US market (3.77%)

Stable Dividend: Whilst dividend payments have been stable, BOPC.F has been paying a dividend for less than 10 years.

Growing Dividend: BOPC.F's dividend payments have increased, but the company has only paid a dividend for 2 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (74.3%), BOPC.F's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of BioPharma Credit's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average board tenure


CEO

BioPharma Credit has no CEO, or we have no data on them.


Board Age and Tenure

2.9yrs

Average Tenure

62.5yo

Average Age

Experienced Board: BOPC.F's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Martin Friedman (54yo)

    Investment Manager

    • Tenure: 0yrs
  • Pablo Legorreta

    Investment Manager

    • Tenure: 0yrs
  • Pedro Gonzalez de Cosio

    Investment Manager

    • Tenure: 0yrs

Board Members

  • Harry Hyman (62yo)

    Senior Independent Director

    • Tenure: 0yrs
    • Compensation: US$70.00k
  • Duncan Budge (63yo)

    Independent Director

    • Tenure: 3yrs
    • Compensation: US$80.35k
  • Jeremy Sillem (69yo)

    Independent Chairman

    • Tenure: 0yrs
    • Compensation: US$100.31k
  • Colin Bond (58yo)

    Independent Director

    • Tenure: 2.9yrs
    • Compensation: US$92.04k
  • Stephanie Léouzon

    Non-Executive Director

    • Tenure: 0.8yrs
    • Compensation: US$5.12k

Company Information

BioPharma Credit PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioPharma Credit PLC
  • Ticker: BOPC.F
  • Exchange: OTCPK
  • Founded: 2016
  • Industry: Asset Management and Custody Banks
  • Sector: Diversified Financials
  • Market Cap: US$1.381b
  • Shares outstanding: 1.37b
  • Website: https://www.bpcruk.com

Location

  • BioPharma Credit PLC
  • Beaufort House
  • 51 New North Road
  • Exeter
  • Devon
  • EX4 4EP
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BPCRLSE (London Stock Exchange)YesOrdinary SharesGBUSDMar 2017
B3PMUN (Boerse Muenchen)YesOrdinary SharesDEEURMar 2017
BPCRLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBUSDMar 2017
BOPC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2017

Biography

BioPharma Credit PLC, an investment trust company, invests in interest-bearing debt assets secured by royalties or other cash flows derived from royalties or sales of approved life sciences products. The c ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 00:28
End of Day Share Price2019/10/08 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.